— Publications

First Nine Months Results 2018

All financial reports

— Media releases

December 17, 2018

Valneva Initiates Phase 2 Clinical Development for its Lyme Disease Vaccine Candidate

Read more

— Financial calendar

Upcoming events
2018 Revenues
February 21, 2019

All dates

— Meet us

Lyme Disease

Download brochure


— Our responsibility

Committed to people, protecting lives and the environment

Learn more

play video Valneva's CEO Thomas Lingelbach
comments on Group Strategy

Subscribe to our Newsletter


Contact Investor Relations


Please update your browser...